DeCode Shares Surge 40 Percent on Skin Cancer SNP Findings | GenomeWeb
NEW YORK (GenomeWeb News) – Shares of DeCode Genetics climbed more than 40 percent today following an announcement that the company had discovered two SNPs associated with the risk of basal cell carcinoma, the most common cancer among people of European ancestry.
 
The boost in DeCode’s shares, which opened at $.36 today and were priced at $.54 in mid-afternoon trading, outpaced a broad rally in the capital markets following a massive sell-off in recent weeks.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.